These sequencing data became more robust in the 2000s with the availability of the Cancer Genome Atlas, which elucidated that aberrations leading to hyperactivation of CCND1/CDK4/6 were specifically common in ER+ breast cancer subtypes [36]. This evidence concerns the gene CDK4 and breast carcinoma.